We found for
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
